Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.

Griffiths, Christopher E M; Gooderham, Melinda; Colombel, Jean-Frederic; Terui, Tadashi; Accioly, Ana P; Gallo, Gaia; Zhu, Danting; Blauvelt, Andrew.

Afiliação

Griffiths CEM; The Dermatology Centre, Salford Royal Hospital, University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, UK.
Gooderham M; SKiN Centre for Dermatology, Peterborough, ON, Canada.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Terui T; Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.
Accioly AP; Eli Lilly and Company, Indianapolis, IN, USA.
Gallo G; Eli Lilly and Company, Indianapolis, IN, USA.
Zhu D; Eli Lilly and Company, Indianapolis, IN, USA.
Blauvelt A; Oregon Medical Research Center, 9495 SW Locust Street, Suite G, Portland, OR, USA. ablauvelt@oregonmedicalresearch.com.

Dermatol Ther (Heidelb) ; 12(6): 1431-1446, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35624407